Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: A correlation with other biological parameters

Histopathology

Volumn 34, Issue 2, 1999, Pages 106-112

  Lee, W Y ^a   Jin, Y T ^a   Chang, T W ^a   Lin, P W ^a   Su, I J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

bcl 2; BRCA1; Breast carcinoma; c erbB 2; Histological grading; p53

Indexed keywords

BRCA1 PROTEIN; ESTROGEN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032912590     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00578.x     Document Type: Article

References (34)

1. Claus EB, Thompson WD, Risch N. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am. J. Hum. Genet. 1991; 48; 232-242.
2. Hall JM, Lee MK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 21; 1684-1689.
3. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266; 66-71.
4. Friedman LS, Ostermeyer EA, Szabo CI et al. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nature Genet. 1994; 8; 399-404.
5. Castilla LH, Couch FJ, Erdos MR et al. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nature Genet. 1994; 8; 387-391.
6. Smith SA, Easton DG, Evans DGR, Ponder BAJ. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet. 1992; 2; 128-131.
7. Futreal PA, Liu QY, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266; 120-122.
8. Merajver SD, Pham RF, Caduff M et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 1995; 9; 439-443.
9. Marquis ST, Rajan JV, Wynshaw-Boris A et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genet. 1995; 11; 17-26.
10. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P. Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev. 1995; 9; 2712-2722.
11. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet. 1995; 9; 445-450.
12. Chen Y, Chen CF, Riley DJ et al. Aberrant subcellular localization of BRCA1 in breast cancer. Science 1995; 270; 789-791.
13. Scully R, Ganesan S, Brown M et al. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996; 272; 123-126.
14. Ruffner H, Verma IM. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc. Natl Acad. Sci. 1997; 94; 7138-7143.
15. Chen Y, Farmer AA, Chen CF et al. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res. 1996; 56; 3168-3172.
16. Zhang HT, Zhang X, Zhao HZ et al. Relationship of p215BRCA1 to tyrosine kinase signaling pathways and the cell cycle in normal and transformed cells. Oncogene 1997; 14; 2863-2869.
17. World Health Organization. Histological typing of breast tumors. International histological classification of tumours, no. 2. 2nd edn. Geneva: World Health Organization, 1981.
18. Page DL, Anderson TJ, Elston CW. Grading of invasive carcinoma of the breast. In Page DL and Anderson TJ eds. Diagnostic histopathology of the breast. New York: Churchill Livingstone, 1987; 300-311.
19. Hsu SM, Raine L, Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem. 1981; 29; 577-580.
20. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 1994; 424; 47-51.
21. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol. 1992; 98; 408-418.
22. Jensen RA, Thompson ME, Jetton TL et al. BRCA1 is secreted and exhibits properties of a granin. Nature Genet. 1996; 12; 303-308.
23. Wilson CA, Payton MN, Pekar SK et al. BRCA1 protein products. Antibody specificity. Nature Genet. 1996; 13; 264-265.
24. Smith TE. Meeting to sort out BRCA1 confusion. Science 1996; 272; 799.
25. Wilson CA, Payton MN, Elliott GS et al. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-Δ11b. Oncogene 1997; 14; 1-16.
26. Thakur S, Zhang HB, Peng Y et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol. Cell. Biol. 1997; 17; 444-452.
27. Wang H, Shao N, Ding QM, Cui J, Reddy ESP, Rao VN. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 1997; 15; 143-157.
28. Rosen PP, Oberman HA. Invasive carcinoma. In Atlas of tumor pathology. Tumors of the mammary gland, 3rd series, fascicle 7. Washington, DC: Armed Forces Institute of Pathology, 1993; 157-168.
29. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
30. Hawkins RA, Roberts MM, Forrest APM. Oestrogen receptors and breast cancer. Current status. Br. J. Surg. 1980; 67; 162-165.
31. Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49; 2087-2090.
32. Thor AD, Moore DH II, Edgerton SM et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl Cancer Inst. 1992; 84; 845-855.
33. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1994; 145; 1191-1198.
34. Gudas JM, Nguyen H, Li T, Cowan KH. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res. 1995; 55; 4561-4565.